CTRI/2019/10/021504
尚未招募
3 期
A phase IIIB/IV randomised open-label trial to compare dolutegravir+ pharmaco-enhanced darunavir versus dolutegravir with predetermined nucleosides versus recommended standard of care antiretroviral regimens in patients with HIV infection who have failed recommended first line therapy: the D2EFT study. - D2EFT
概览
- 阶段
- 3 期
- 干预措施
- 未指定
- 疾病 / 适应症
- Health Condition 1: B20- Human immunodeficiency virus [HIV]disease
- 发起方
- niversity of New South Wales
- 状态
- 尚未招募
- 最后更新
- 4年前
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- •1\. HIV\-1 positive by licensed diagnostic test
- •2\. Aged \>\=18 years of age
- •3\. Failed first\-line non\-nucleoside reverse transcriptase inhibitor (NNRTI) \+ 2NRTI combination therapy according to virological criteria, defined as at least two consecutive (\>\=7 days apart) pVL results \>500 copies/mL after a minimum period of exposure to continuous NNRTI \+ 2NRTI firstline therapy of 24 weeks (only the second pVL result needs to be within 45 days of randomisation)
- •4\. For women of child\-bearing potential, willingness to use appropriate contraception
- •5\. Able to provide written informed consent
排除标准
- 未提供
结局指标
主要结局
未指定
相似试验
进行中（未招募）
1 期
A Phase IIIb, randomised, open label study to compare the safety, efficacy and tolerability of anagrelide hydrochloride versus hydroxyurea in high-risk essential thrombocythaemia patients.Essential thrombocythaemia (ET)MedDRA version: 7.1Level: LLTClassification code 10015493EUCTR2004-004061-15-ESShire Pharmaceutical Development Ltd.146
进行中（未招募）
1 期
A Phase IIIb, randomised, open label study to compare the safety, efficacy and tolerability of anagrelide hydrochloride versus hydroxyurea in high-risk essential thrombocythaemia patients.Essential thrombocythaemia (ET)MedDRA version: 7.1Level: LLTClassification code 10015493EUCTR2004-004061-15-IEShire Pharmaceutical Development Ltd.184
进行中（未招募）
不适用
A Phase IIIb, randomised, open label study to compare the safety, efficacy and tolerability of anagrelide hydrochloride versus hydroxyurea in high-risk essential thrombocythaemia patients.Essential thrombocythaemiaMedDRA version: 12.0Level: LLTClassification code 10015493Term: Essential thrombocythaemiaEUCTR2004-004061-15-PLShire Pharmaceutical Development Ltd.184
进行中（未招募）
1 期
A Phase IIIb, randomised, open label study to compare the safety, efficacy and tolerability of anagrelide hydrochloride versus hydroxyurea in high-risk essential thrombocythaemia patients.EUCTR2004-004061-15-BEShire Pharmaceutical Development Ltd.146
进行中（未招募）
1 期
A study to compare the safety and effectiveness of anagrelide and hydroxyurea in high-risk essential thrombocythaemia patients.Essential thrombocythaemiaMedDRA version: 14.0Level: PTClassification code 10015493Term: Essential thrombocythaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2004-004061-15-BGShire Pharmaceutical Development Ltd.184